Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

Cited by (1,110)

Items 601–700 of 1,110

1. Cardiovascular Outcomes in Patients With Previous Myocardial Infarction and Mild Diabetes Mellitus Following Treatment With Pioglitazone
   Masanori Asakura, Jiyoong Kim, Hiroshi Asanuma, Yasuharu Nakama, Kengo Tsukahara, Yorihiko Higashino, Tetsuya Ishikawa, Shinji Koba, Mitsuru Tsujimoto, Hideo Himeno et al. · 2018 · EClinicalMedicine
2. Prevención de ictus en pacientes con diabetes mellitus tipo 2 o prediabetes. Recomendaciones del Grupo de Estudio de Enfermedades Cerebrovasculares de la Sociedad Española de Neurología
   Fuentes, B., Amaro, S., Alonso de Leciñana, M., Arenillas, J.F., Ayo-Martín, O., Castellanos, M., Freijo, M., García-Pastor, A., Gomis, M., Gómez Choco, M. et al. · 2021 · Neurología
3. 2019 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD
   Cosentino, Francesco, Grant, Peter J, Aboyans, Victor, Bailey, Clifford J, Ceriello, Antonio, Delgado, Victoria, Federici, Massimo, Filippatos, Gerasimos, Grobbee, Diederick E, Hansen, Tina Birgitte et al. · 2020 · European Heart Journal
4. Potential Molecular Biomarkers for Predicting and Monitoring Complications in Type 2 Diabetes Mellitus
   Zia Shariat‐Madar, Fakhri Mahdi · 2025 · Molecules
5. The relationship between dietary intake of live microbes and insulin resistance among healthy adults in the US: a cross-sectional study from NHANES 2003–2020
   Shicheng Gu, Chenyu Jiang, Zhenjun Yu, Wenyuan Yang, Chaoqun Wu, Yaojian Shao · 2024 · Scientific Reports
6. Approach to Lipid Management in the Patient With Diabetes
   Stephanie J. Kim, Savitha Subramanian · 2025 · The Journal of Clinical Endocrinology & Metabolism
7. Post-stroke cognitive impairment and the risk of stroke recurrence and death in patients with insulin resistance
   Kat Schmidt, Melinda C. Power, Adam Ciarleglio, Zurab Nadareishvili · 2022 · Journal of Stroke and Cerebrovascular Diseases
8. Therapeutic Approaches for Nonalcoholic Fatty Liver Disease: Established Targets and Drugs
   Xiaojing Huang, Huiling Chen, Song Wen, Meiyuan Dong, Ligang Zhou, Xinlu Yuan · 2023 · Diabetes Metabolic Syndrome and Obesity
9. Detecting pioglitazone use and risk of cardiovascular events using electronic health record data in a large cohort of Chinese patients with type 2 diabetes
   Shumei Miao, Xiao Dong, Xin Zhang, Shenqi Jing, Xiaoliang Zhang, Tingyu Xu, Li Wang, Xianglin L. Du, Hua Xu, Yun Liu · 2018 · Journal of Diabetes
10. Impaired cross-talk between NO and hyperpolarization in myoendothelial feedback: a novel therapeutic target in early endothelial dysfunction of metabolic disease
    Rana A. Alaaeddine, Ali Mroueh, Stephen L. Gust, Ali Hussein Eid, Frances Plane, Ahmed Fawzy EL‐Yazbi · 2019 · Current Opinion in Pharmacology
11. Prevalence of pre-existing dysglycaemia among inpatients with acute coronary syndrome and associations with outcomes
    Dinesh C. Mahendran, Garry W. Hamilton, Jeremy Weiss, Leonid P. Churilov, Jeremy Lew, Kaylyn Khoo, Que T. Lam, Raymond Robbins, Graeme K. Hart, Douglas Forsyth Johnson et al. · 2019 · Diabetes Research and Clinical Practice
12. Prediabetes: lifestyle, pharmacotherapy or regulation?
    Jonathan E. Shaw · 2019 · Therapeutic Advances in Endocrinology and Metabolism
13. Low Reporting of Cointerventions in Recent Cardiovascular Clinical Trials: A Systematic Review
    Elisavet Moutzouri, Luise Adam, Martin Feller, Lamprini Syrogiannouli, Bruno R. da Costa, Cinzia Del Giovane, Douglas C. Bauer, Drahomir Aujesky, Arnaud Chioléro, Nicolas Rodondi · 2020 · Journal of the American Heart Association
14. Lack of association between insulin resistance as estimated by homeostasis model assessment and stroke risk: A systematic review and meta-analysis
    Tianyi Gu, Qiguo Yang, Guangyu Ying · 2020 · Medical Hypotheses
15. Two Unique Mutations in HTRA1-Related Cerebral Small Vessel Disease in North America and Africa and Literature Review
    Ty Shang, Marco C. Pinho, Debarti Ray · 2021 · Journal of Stroke and Cerebrovascular Diseases
16. Pioglitazone and Prostate Cancer Risk in Taiwanese Male Patients with Type 2 Diabetes: A Retrospective Cohort Study
    Chin‐Hsiao Tseng · 2022 · The World Journal of Men s Health
17. Thiazolidinediones (TZDs)
    Jong Chul Won · 2021 · Stroke revisited
18. Reducing sedentary time and fat mass may improve glucose tolerance and insulin sensitivity in adults surviving 6 months after stroke: A phase I pilot study
    Karen Borschmann, Elif Ilhan Ekinci, Sandra Iuliano, Leonid P. Churilov, Marco Y.C. Pang, Julie A Bernhardt · 2017 · European Stroke Journal
19. Understanding the cardiovascular risk with non-insulin antidiabetic drugs
    Vasilios Gabriel Athyros, Konstantinos P. Imprialos, Konstantinos Stavropoulos, Alexandros Sahinidis, Michael N. Doumas · 2019 · Expert Opinion on Drug Safety
20. Effects of glucose-lowering drugs on cardiovascular outcomes in patients with type 2 diabetes
    Brian Tomlinson, Miao Hu, Yuzhen Zhang, Paul Chan, Zhong-Min Liu · 2016 · Expert Opinion on Drug Metabolism & Toxicology
21. Cardiovascular Outcomes of New Medications for Type 2 Diabetes
    Jennifer M. Trujillo, Sara A. Wettergreen, Wesley A. Nuffer, Samuel L. Ellis, Michael T. McDermott · 2016 · Diabetes Technology & Therapeutics
22. Revisiting The Use of Pioglitazone in the Treatment of Type 2 Diabetes
    DANIEL F. EINHORN, Vivian Andrew Fonseca · 2016 · Endocrine Practice
23. Association between insulin resistance and post-ischaemic stroke outcome in patients without diabetes: protocol for a systematic review and meta-analysis
    Jeremiah Hadwen, Woojin Kim, Brian Dewar, Tim Ramsay, Alexandra Davis, Dar D Dowlatshahi, Michel Christopher Frank Shamy · 2021 · BMJ Open
24. Will lobeglitazone rival pioglitazone? A systematic review and critical appraisal
    Kalyan Kumar Gangopadhyay, Awadhesh Kumar Singh · 2023 · Diabetes & Metabolic Syndrome Clinical Research & Reviews
25. In-vitro antiplatelet effect of melatonin in healthy individuals and patients with type 2 diabetes mellitus
    Allan Böhm, V. Lauko, K Dostalova, I. Balanova, I Varga, Branislav Bezák, Nikola Jajcay, Roman Moravčík, L Lazurova, P Slezak et al. · 2023 · Journal of Endocrinological Investigation
26. Novel Anti-glycemic Drugs and Reduction of Cardiovascular Risk in Diabetes: Expectations Realized, Promises Unmet
    James Flory, Jenny Ukena, James S. Floyd · 2016 · Current Atherosclerosis Reports
27. Recent advances in understanding/managing type 2 diabetes mellitus
    Pablo J. Aschner · 2017 · F1000Research
28. Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?
    Muhammad A Abdul‐Ghani, Amin Jayyous, Nidal Asaad, Sherif Helmy, Jassim M. S. Al Suwaidi · 2018 · Annals of Translational Medicine
29. Cardiovascular and Renal Outcomes of Newer Anti-Diabetic Medications in High-Risk Patients
    Lima Lawrence, Venu Menon, Sangeeta Rao Kashyap · 2018 · Current Cardiology Reports
30. Effect of thiazolidinedione therapy on the risk of uric acid stones
    John Robert Asplin, David S. Goldfarb · 2019 · Kidney International
31. Type 2 diabetes: Evolving concepts and treatment
    Eden M Miller, Richard B. Aguilar, Mary E. Herman, Stanley S. Schwartz · 2019 · Cleveland Clinic Journal of Medicine
32. Management and prevention of cardiovascular disease for type 2 diabetes: Integrating the diabetes management recommendations of AACE, ADA, EASD, AHA, ACC, and ESC
    Zachary T. Bloomgarden, Yehuda Handelsman · 2020 · American Journal of Preventive Cardiology
33. Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society
    Raffaele Napoli, Gloria Formoso, Salvatore Piro, Giovanni Targher, Agostino Consoli, Francesco Purrello · 2020 · Nutrition Metabolism and Cardiovascular Diseases
34. L-carnitine supplementation ameliorates insulin resistance in critically ill acute stroke patients
    Malihe Nejati, Saeed Abbasi, Shadi Farsaei, Fatemeh Shafiee · 2021 · Research in Pharmaceutical Sciences
35. Association between changes in bodyweight and cardiovascular disease risk factors among obese Japanese patients with type 2 diabetes
    Ran Yoshimura, Tomoko Nakagami, Yukiko Hasegawa, Junko Oya, Tetsuya Babazono · 2022 · Journal of Diabetes Investigation
36. Rethinking the role of pioglitazone in modern diabetology as a cardiorenoprotective agent
    В. В. Салухов, Ковалевская Елена Анатольевна · 2022 · Meditsinskiy sovet = Medical Council
37. Insulin resistance is associated with an unfavorable outcome among non-diabetic patients with isolated moderate-to-severe traumatic brain injury – A propensity score-matched study
    Cheng Cao, Huxu Wang, Heng Gao, Wei Wu · 2022 · Frontiers in Neurology
38. Trends in lipid profile and lipid control among survivors of stroke or myocardial infarction among US adults, 2001–2018
    Weiwei Dong, Zhiyong Yang · 2023 · Frontiers in Endocrinology
39. Body mass index and waist circumference as predictors of recurrent vascular events after a recent ischemic stroke
    Kyusik Kang, Jong‐Moo Park, Wi‐Sun Ryu et al. · 2023 · Journal of Stroke and Cerebrovascular Diseases
40. Predictive value of serum pregnancy-associated plasma protein A for patients with ischemic cerebrovascular disease
    Shun Wang, Jun Jiang, Chuncheng Qu · 2016 · Journal of Clinical Laboratory Analysis
41. Power of an Adaptive Trial Design for Endovascular Stroke Studies
    Maarten G. Lansberg, Ninad S. Bhat, Sharon D. Yeatts · 2016 · Stroke
42. Pleural Effusion Due to Use of Pioglitazone: A Case Report
    Jinhui Xue, Wei Liu, Fang‐Hong Shi, Jun Zheng, Jing Ma · 2020 · Metabolic Syndrome and Related Disorders
43. Nonalcoholic fatty liver disease and the risk of metabolic comorbidities: how to manage in clinical practice
    Carolina María Perdomo, Paola D’Ingianna, Javier Escalada, Salvatore Petta, Manuel Romero‐Gómez, Javier Ampuero · 2020 · Polskie Archiwum Medycyny Wewnętrznej
44. New Hope For People With Dysglycemia and Cardiovascular Disease Manifestations
    Lars Rydén, Linda Mellbin · 2017 · Circulation
45. Treating Diabetes to Prevent Stroke
    Walter N. Kernan, Silvio E. Inzucchi · 2021 · Stroke
46. Advances and counterpoints in type 2 diabetes. What is ready for translation into real-world practice, ahead of the guidelines
    Stanley S. Schwartz, Barbara E. Corkey, James R. Gavin, Ralph A. DeFronzo, Mary E. Herman · 2024 · BMC Medicine
47. Association between estimated glucose disposal rate and lower extremity arterial disease in type 2 diabetes: A nationwide cross‐sectional study from China
    Xu Wei, Jie Zhao, Ping Zhu, Wenfang Niu, Zhangrong Xu, Xingwu Ran, Xiaomei Zhang, Aihong Wang, Linong Ji · 2025 · Diabetes Obesity and Metabolism
48. Current treatment guidelines and glycated haemoglobin goals for type 2 diabetes: Which patients are most likely to benefit from fixed‐ratio basal insulin glucagon‐like peptide‐1 receptor agonist combinations?
    Kevin Cowart, Nicholas W. Carris · 2025 · Diabetes Obesity and Metabolism
49. Joint association of estimated glucose disposal rate and aggregate index of systemic inflammation with mortality in general population: a nationwide prospective cohort study
    Ruosen Yuan, Yao Zhao, He Yuan · 2026 · Cardiovascular Diabetology
50. A Review of Cardiovascular Outcomes Trials of Glucose-Lowering Therapies and Their Effects on Heart Failure Outcomes
    Michael E. Nassif, Mikhail Kosiborod · 2019 · The American Journal of Medicine
51. Efficacy and Safety of Alogliptin-Pioglitazone Combination for Type 2 Diabetes Mellitus Poorly Controlled with Metformin: A Multicenter, Double-Blind Randomized Trial
    Ji-Yeon Park, Joonyub Lee, Yoon‐Hee Choi, Kyung Wan Min, Kyung Ah Han, Kyu Jeung Ahn, Soo Kun Lim, Younghyun Kim, Chul Woo Ahn, Kyung Mook Choi et al. · 2024 · Diabetes & Metabolism Journal
52. Treating Type 2 Diabetes With Early, Intensive, Multimodal Pharmacotherapy: Real‐World Evidence From an International Collaborative Database
    Matthew Anson, Ayesha Ikram Malik, Sizheng Steven Zhao, Philip J. Austin, Gema Hernández, Shabbar S. Jaffar, Anupam V. Garrib, Daniel James Cuthbertson, Uazman Alam · 2024 · Journal of Diabetes Research
53. What Can We Learn from Interventions That Change Fat Distribution?
    Pornpoj Pramyothin, Kalypso Karastergiou · 2016 · Current Obesity Reports
54. Diabetes medications with cardiovascular protection – what now after LEADER®? Could metformin, pioglitazone, empagliflozin and liraglutide complement each other to save lives?
    Robert E. J. Ryder, Ralph Anthony DeFronzo · 2016 · British Journal of Diabetes
55. Implications of the EMPA-REG Trial for Clinical Care and Research
    Angeliki M. Stamatouli, Silvio E. Inzucchi · 2016 · Current Diabetes Reports
56. Have we really demonstrated the cardiovascular safety of anti‐hyperglycaemic drugs? Rethinking the concepts of macrovascular and microvascular disease in type 2 diabetes
    Milton Packer · 2018 · Diabetes Obesity and Metabolism
57. Personalizing Glucose-Lowering Therapy in Patients with Type 2 Diabetes and Cardiovascular Disease
    Silvio E. Inzucchi · 2018 · Endocrinology and Metabolism Clinics of North America
58. Positionspapier zur Diagnostik und Therapie der peripheren arteriellen Verschlusskrankheit (pAVK) bei Menschen mit Diabetes mellitus
    Bernd M. Balletshofer, Wulf D. Ito, Holger Lawall, Nasser M. Malyar, Yves Oberländer, Peter Reimer, Kilian Rittig, Markus Zähringer · 2019 · Der Diabetologe
59. Pioglitazone and breast cancer risk in female patients with type 2 diabetes mellitus: a retrospective cohort analysis
    Chin‐Hsiao Tseng · 2022 · BMC Cancer
60. Statins and renal disease progression, ophthalmic manifestations, and neurological manifestations in veterans with diabetes: A retrospective cohort study
    Ishak A. Mansi, Matheu Chansard, Ildiko Lingvay, Song Zhang, Ethan A. Halm, Carlos A. Álvarez · 2022 · PLoS ONE
61. Impact of Free Fatty Acids on Vascular Insulin Responses Across the Arterial Tree: A Randomized Crossover Study
    Kaitlin M. Love, Linda A. Jahn, Lee M. Hartline, Kevin W. Aylor, Zhenqi Liu · 2023 · The Journal of Clinical Endocrinology & Metabolism
62. The Association between Impaired Glucose Regulation and Prognosis of Chinese Patients with Intracerebral Hemorrhage
    Shichao Sun, Yuesong Pan, Xingquan Zhao, Liping Liu, Hao Li, Yan Ling He, Li Guo, Yilong Wang, Yongjun Wang · 2016 · Scientific Reports
63. Metabolic effects of antihyperglycemic agents and mortality: meta-analysis of randomized controlled trials
    Dimitris Rucks Varvaki Rados, Camila Viecceli, Lana Catani Ferreira Pinto, Fernando Gerchman, Cristiane Bauermann Leitão, Jorge Luiz Gross · 2020 · Scientific Reports
64. Chiglitazar: a novel pan-PPAR agonist
    Ralph A. DeFronzo · 2021 · 中国科学通报：英文版
65. Extra-Glycemic Effects of Anti-Diabetic Medications: Two Birds with One Stone?
    Eun‐Jung Rhee · 2022 · Endocrinology and Metabolism
66. Evaluation of the HbA1c Reduction Cut Point for a Nonglycemic Effect on Cardiovascular Benefit of Hypoglycemic Agents in Patients with Type 2 Diabetes Based on Endpoint Events
    Yuchao Wu, Lizhi Tang, Fang Zhang, Zhe Yan, Jing Li, Nanwei Tong · 2018 · International Journal of Endocrinology
67. Dyslipidemia in Diabetes
    Savitha Subramanian, Alan Chait · 2018 · Elsevier eBooks
68. Pioglitazone Use After Stroke
    Jesse Dawson · 2018 · Circulation
69. Cardiovascular Disease in Diabetes
    Marie‐Ève Piché, Paul Poirier · 2018 · Elsevier eBooks
70. Diabetes und Zentralnervensystem
    Frank Joachim Erbguth · 2017 · Der Nervenarzt
71. Current Treatment Options, Including Diet, Exercise, and Medications
    Mazen Noureddin, Manal F. Abdelmalek · 2023 · Clinics in Liver Disease
72. Recent Insights into Pharmacologic Cardiovascular Risk Reduction in Type 2 Diabetes Mellitus
    Scott L. Purga, Mandeep S. Sidhu, Michael E. Farkouh, Joshua Schulman‐Marcus · 2017 · Cardiovascular Drugs and Therapy
73. Effects of glucose-lowering agents on ischemic stroke
    Konstantinos Ioannis Avgerinos, Κωνσταντίνος Τζιόμαλος · 2017 · World Journal of Diabetes
74. First cardiovascular event in patients with type 2 diabetes mellitus of a cardiovascular risk management program of a poor Colombian population: a cohort study
    Pablo Andrés Miranda Machado, Fernando Salcedo‐Mejía, Justo Paz Wilches, J.C. Fernandez-Mercado, Fernando de la Hoz, Nelson Alvis‐Guzmán · 2019 · BMC Cardiovascular Disorders
75. Evolving Concepts of Type 2 Diabetes Management
    Layla A. Abushamat, Jane E.B. Reusch · 2021 · Medical Clinics of North America
76. Glucose-lowering therapy in patients undergoing percutaneous coronary intervention
    Isabelle Johansson, Ilaria Dicembrini, Edoardo Mannucci, Francesco Cosentino · 2021 · EuroIntervention
77. Evidence-based therapeutics for hyperglycemia in hospitalized noncritically ill patients
    Abraham Edgar Gracia‐Ramos, Juana Carretero‐Gómez, Carlos E. Mendez, Francisco Javier Carrasco-Sánchez · 2021 · Current Medical Research and Opinion
78. Downregulation of mitochondrial pyruvate carrier 2 aggravates neuronal injury in the cortex following cerebral ischemia in rat
    Yue Wang, Yue Liu, Yuan Yuan, Ying Zhang, Yanlin Luo, Song Han, Yi Yan, Zhaohui Wang, Xiao Liu, Li Zhao · 2022 · Brain Research Bulletin
79. Expert consensus on personalized initiation of glucose‐lowering therapy in adults with newly diagnosed type 2 diabetes without clinical cardiovascular disease or chronic kidney disease
    Fang Zhang, Linong Ji, Tianpei Hong, Lixin Guo, Yan Li, Zhiming Zhu, Xingbin Liu, Fang Liu, Lizhi Tang, Yuwei Zhang et al. · 2022 · Journal of Evidence-Based Medicine
80. Rosiglitazone Does Not Affect the Risk of Inflammatory Bowel Disease: A Retrospective Cohort Study in Taiwanese Type 2 Diabetes Patients
    Chin‐Hsiao Tseng · 2023 · Pharmaceuticals
81. Diabetes and susceptibility to COVID-19: Risk factors and preventive and therapeutic strategies
    Jingwen Liu, Xiao Jun Huang, Mingke Wang, Jishun Yang · 2024 · World Journal of Diabetes
82. Effectiveness of metformin pretreatment for stroke severity: A propensity score matching study
    Bowei Zhang, Scott B. Silverman, Lee H. Schwamm · 2024 · CNS Neuroscience & Therapeutics
83. The Insulin Resistance Intervention after Stroke trial: A perspective on future practice and research
    Philip M. Bath, Jason P. Appleton, Nikola Sprigg · 2016 · International Journal of Stroke
84. Effects of functional CYP2C8,CYP2C9,CYP3A5,and ABCB1 genetic variants on the pharmacokinetics of insulin sensitizer pioglitazone in Chinese Han individuals
    Shengju Yin, Hui-Min Qi, Xin Wang, Pu Zhang, Yuan Lü, Min‐Ji Wei, Pu Li, Guangzhao Qi, Ya‐Qing Lou, Chuang Lu et al. · 2017 · Pharmacogenetics and Genomics
85. Pharmacological Prevention of Cardiovascular Outcomes in Diabetes Mellitus: Established and Emerging Agents
    David R. Saxon, Neda Rasouli, Robert H. Eckel · 2018 · Drugs
86. Pharmacological management of cerebral ischemia in the elderly
    Adithya Kannan, Mychael W. Delgardo, William Pennington-FitzGerald, Enoch X Jiang, Brandon R. Christophe, Edward Sander Connolly · 2020 · Expert Opinion on Pharmacotherapy
87. MLR-1023 Treatment in Mice and Humans Induces a Thermogenic Program, and Menthol Potentiates the Effect
    Candida Joan Rebello, Ann A. Coulter, Andrew G. Reaume, Wei-na Cong, Luke A. Cusimano, Frank L. Greenway · 2021 · Pharmaceuticals
88. Antihyperglykämische Therapie bei Diabetes mellitus Typ 2 (Update 2023)
    Martin Clodi, Heidemarie Abrahamian, Helmut Brath, Guntram Schernthaner, Johann Brix, Bernhard H. Ludvik, Heinz Drexel, Christoph H. Saely, Peter Fasching, Gersina Rega‐Kaun et al. · 2023 · Wiener klinische Wochenschrift
89. The IRIS (Insulin Resistance Intervention after Stroke) trial: A new perspective on pioglitazone
    Silvio E. Inzucchi, Karen L. Furie · 2016 · Journal of Diabetes
90. Antidiabéticos en prevención de ictus en pacientes con diabetes tipo 2. El punto de vista del neurólogo
    Blanca Fuentes · 2017 · Medicina Clínica
91. Clinical implications of cardiovascular outcome trials in type 2 diabetes
    L. Mellbin, A. Wang, L. Rydén · 2019 · Herz
92. Linking Estimated Glucose Disposal Rate to Major Adverse Cardio-Cerebrovascular Events in Populations With and Without Diabetes: A Systematic Review and Meta-Analysis
    Shayan Shojaei, Hanieh Radkhah, Alireza Azarboo, Pedram Soltani, Sadaf Esteki, Asma Mousavi · 2025 · Clinical Medicine Insights Endocrinology and Diabetes
93. Metabolic liver disease: A summary of major guidelines and identifying opportunities to improve future guidelines
    Fernando Bril · 2026 · Diabetes Obesity and Metabolism
94. METTL14 inhibits atherogenesis by epigenetically activating PPAR-α/γ transcription and fatty acid oxidation in VSMCs
    Lei Cui, Cheng Kiu Ho, 梁盼红, Wentao Gao, Jitao Liu, Xiao Yu Tian, Randolph H.L. Wong, Bin Zhou, Kathy O. Lui · 2026 · Cardiovascular Research
95. Rosiglitazone improves insulin resistance but does not improve exercise capacity in individuals with impaired glucose tolerance: A randomized clinical study
    Layla A. Abushamat, Irene E. Schauer, Cecilia C. Low Wang, Stacey Mitchell, Leah Herlache, Mark Bridenstine, R. J. Durbin, Janet K. Snell‐Bergeon, Judith G. Regensteiner, Jane E.B. Reusch · 2023 · Journal of Investigative Medicine
96. Diabetes: a potential mediator of associations between polycyclic aromatic hydrocarbon exposure and stroke
    Aikai Zhang, Hongda Zhang, Lijie Mi, Lei Ding, Zihan Jiang, Fengyuan Yu, Min Tang · 2024 · Environmental Science and Pollution Research
97. Reassessing the Risk-Benefit Profile of Thiazolidinediones: Cardiovascular Risks and Stroke Prevention Through Real-World Data
    Fei Lu, Yingjie Zhao · 2025 · Endocrine Practice
98. Management of Type 2 Diabetes Mellitus
    Leslie Bahn Kawa · 2023 · IntechOpen eBooks
99. Peroxisome proliferator-activated receptorα/γ agonist pioglitazone for rescuing relapsed or refractory neoplasias by unlocking phenotypic plasticity
    Dennis Christoph Harrer, Florian Lüke, Tobias Pukrop, Lina Ghibelli, Christopher Gerner, Albrecht Reichle, Daniel Heudobler · 2024 · Frontiers in Oncology
100. Cancer biology in diabetes update: Focusing on antidiabetic drugs
     Emi Kawakita, Keizo Kanasaki · 2024 · Journal of Diabetes Investigation